Chiao-Yu Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chiao-Yu Cheng has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Chang-Hsueh Wu
Department of Pharmacology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
1 shared publication- Cheng-Hsien Tsai
Natl Taiwan Univ Hosp, Dept Pediat, Yunlin Branch, 579, Sec 2, Yunlin Rd, Touliu 640203, Yunlin, Taiwan
1 shared publication Chia-Jui Du
Pediatrics
1 shared publicationChien-Yu Lin
Institute of Statistical Science Academia Sinica, Taipei, Taiwan
1 shared publicationChih-Hsiang Yu
Institute of Statistical Science Academia Sinica, Taipei, Taiwan
1 shared publicationChun-Yi Chi
Natl Taiwan Univ Hosp, Dept Med Nephrol, Yunlin Branch, Touliu, Yunlin, Taiwan
1 shared publication
Latest Publications
- 9 December 2025
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (1) , 32-39
Preemptive NUDT15 Genotyping and Its Impact on Febrile Neutropenia in Pediatric Patients With Acute Lymphoblastic Leukemia in Taiwan
This study investigated whether preemptive NUDT15 genotyping can reduce episodes of febrile neutropenia during the continuation phase of acute lymphoblastic leukemia (ALL) treatment. This retrospective cohort study enrolled 243 children with ALL who were treated according to the Taiwan Pediatric Oncology Group protocol at the National Taiwan University Hospital. The patients were divided into those who underwent preemptive NUDT15 genotyping (n=30) and historical controls (n=213). Febrile neutropenia episodes were compared between groups stratified by risk classification (standard risk [SR], high-risk [HR], very high-risk [VHR] groups). Multivariate analysis was performed, and the dosage was adjusted for age, sex, and mercaptopurine. Preemptive genotyping did not significantly reduce febrile neutropenia episodes in the SR, HR, and VHR patient groups—although a general trend toward reduction was observed. VHR patients with compound heterozygous NUDT15 polymorphisms had a significantly higher risk (risk ratio: 5.6, P =0.001). Younger age at diagnosis was determined to be a predictor of febrile neutropenia. Preemptive NUDT15 genotyping did not significantly reduce febrile neutropenia episodes in our cohort of pediatric patients with ALL, although it allowed a potential reduction in HR patients. Clinicians should consider preemptive testing, particularly in HR and VHR patient groups, to optimize ALL treatments and reduce adverse events.
- 9 December 2025
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (1) , 32-39
Preemptive NUDT15 Genotyping and Its Impact on Febrile Neutropenia in Pediatric Patients With Acute Lymphoblastic Leukemia in Taiwan
This study investigated whether preemptive NUDT15 genotyping can reduce episodes of febrile neutropenia during the continuation phase of acute lymphoblastic leukemia (ALL) treatment. This retrospective cohort study enrolled 243 children with ALL who were treated according to the Taiwan Pediatric Oncology Group protocol at the National Taiwan University Hospital. The patients were divided into those who underwent preemptive NUDT15 genotyping (n=30) and historical controls (n=213). Febrile neutropenia episodes were compared between groups stratified by risk classification (standard risk [SR], high-risk [HR], very high-risk [VHR] groups). Multivariate analysis was performed, and the dosage was adjusted for age, sex, and mercaptopurine. Preemptive genotyping did not significantly reduce febrile neutropenia episodes in the SR, HR, and VHR patient groups—although a general trend toward reduction was observed. VHR patients with compound heterozygous NUDT15 polymorphisms had a significantly higher risk (risk ratio: 5.6, P =0.001). Younger age at diagnosis was determined to be a predictor of febrile neutropenia. Preemptive NUDT15 genotyping did not significantly reduce febrile neutropenia episodes in our cohort of pediatric patients with ALL, although it allowed a potential reduction in HR patients. Clinicians should consider preemptive testing, particularly in HR and VHR patient groups, to optimize ALL treatments and reduce adverse events.
- Open Access
- 4 February 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (1) , 753-760
Ruxolitinib for pediatric acute and chronic graft-versus-host disease: a single-center retrospective study of efficacy and safety
Graft-versus-host disease (GVHD) is a major concern for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Ruxolitinib has been proven effective in treating adult steroid-refractory GVHD; however, studies on pediatric patients are relatively scarce. Thus, this single-center study evaluated the efficacy and safety of ruxolitinib in pediatric patients with steroid-refractory GVHD. We retrospectively reviewed the data of patients aged < 18 years who underwent allogeneic HSCT and received ruxolitinib treatment for either acute GVHD (aGVHD) or chronic GVHD (cGVHD) between 2018 and 2023. Data on the clinical response, concomitant and subsequent medications, adverse events, and outcomes were obtained through medical chart review. Sixteen patients were analyzed in this study: seven with aGVHD and nine with cGVHD. The overall response rate for the 16 patients was 81% (aGVHD, 86%; cGVHD, 77%). The overall survival rate was 56%: (aGVHD, 57%; cGVHD, 55%). For 11 patients with at least stable disease, steroid dosage could be reduced by at least 75%; however, corticosteroids were successfully tapered off in only six patients at the last follow-up. Among four patients with documented lung cGVHD, none experienced lung cGVHD progression at 1-year follow-up. Further, 50% of the patients experienced grade 3 or 4 neutropenia and/or thrombocytopenia, and 56% had viral reactivation. Two patients discontinued ruxolitinib owing to adverse events. Ruxolitinib treatment for pediatric patients with aGVHD and cGVHD is associated with a high overall response rate, significant steroid-sparing effect, acceptable toxicity, and manageable adverse events. However, blood count and viral reactivation should be closely monitored during ruxolitinib use.
- 4 February 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (1) , 753-760
Open AccessRuxolitinib for pediatric acute and chronic graft-versus-host disease: a single-center retrospective study of efficacy and safety
Graft-versus-host disease (GVHD) is a major concern for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Ruxolitinib has been proven effective in treating adult steroid-refractory GVHD; however, studies on pediatric patients are relatively scarce. Thus, this single-center study evaluated the efficacy and safety of ruxolitinib in pediatric patients with steroid-refractory GVHD. We retrospectively reviewed the data of patients aged < 18 years who underwent allogeneic HSCT and received ruxolitinib treatment for either acute GVHD (aGVHD) or chronic GVHD (cGVHD) between 2018 and 2023. Data on the clinical response, concomitant and subsequent medications, adverse events, and outcomes were obtained through medical chart review. Sixteen patients were analyzed in this study: seven with aGVHD and nine with cGVHD. The overall response rate for the 16 patients was 81% (aGVHD, 86%; cGVHD, 77%). The overall survival rate was 56%: (aGVHD, 57%; cGVHD, 55%). For 11 patients with at least stable disease, steroid dosage could be reduced by at least 75%; however, corticosteroids were successfully tapered off in only six patients at the last follow-up. Among four patients with documented lung cGVHD, none experienced lung cGVHD progression at 1-year follow-up. Further, 50% of the patients experienced grade 3 or 4 neutropenia and/or thrombocytopenia, and 56% had viral reactivation. Two patients discontinued ruxolitinib owing to adverse events. Ruxolitinib treatment for pediatric patients with aGVHD and cGVHD is associated with a high overall response rate, significant steroid-sparing effect, acceptable toxicity, and manageable adverse events. However, blood count and viral reactivation should be closely monitored during ruxolitinib use.
- Open Access
- 25 November 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122 (2) , 182-186
Successful treatment of acute encephalitis and hepatitis in a child with COVID-19 infection
- 25 November 2022
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122 (2) , 182-186
Open AccessSuccessful treatment of acute encephalitis and hepatitis in a child with COVID-19 infection
- Open Access
- 23 March 2022
- Published by Elsevier in Pediatrics & Neonatology
- Vol. 63 (4) , 428-429
Ruptured omphalocele with ischemic bowels
- 23 March 2022
- Published by Elsevier in Pediatrics & Neonatology
- Vol. 63 (4) , 428-429
Open AccessRuptured omphalocele with ischemic bowels